Clinical Trials Logo

Dermatitis, Atopic clinical trials

View clinical trials related to Dermatitis, Atopic.

Filter by:

NCT ID: NCT01291940 Completed - Atopic Dermatitis Clinical Trials

The Effects of Emollient Therapy on the Skin Barrier

EES
Start date: January 2011
Phase: N/A
Study type: Interventional

The goal of this study is to better understand what effect emollients (moisturizers) have on the skin in young children and adults. Subjects will be recruited from PI and Sub-I clinics and Oregon Health & Science University (OHSU) research opportunities website. 1. Adult and Adolescent Study: Moisturizer Intervention - There will be 2-3 visits for this study: a screening visit, a baseline visit, and a final visit. Adults with a history of eczema will be asked to apply one of four possible moisturizers to one arm and nothing to the other arm for four weeks. The moisturizers, which will be assigned to the subjects, include either Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, or Vaseline 100% Petroleum Jelly. Subjects can use other skin treatments as needed for their skin condition, but may not treat the arms during the study. Non-invasive tests of the skin will be made at Visit 1 and after four weeks (Visit 2). The skin measurements that will be performed are: - Transepidermal loss (TEWL)- measures how much water is lost across the skin barrier - Skin Cohesion and TEWL - TEWL after 5, 10, 15, and 20 tape strips will measure skin barrier function after tape-stripping - Skin electrical capacitance - measures the moisture in the top layer of skin - Skin pH - measures the acidity of the skin - Stratum corneum cohesion assay - tape-stripping to measure the protein removed from the top layer of skin - Lipidomic analysis - measures the lipids, or oils, in the top layer of skin Control - There will be 1-2 visits for this group: a screening visit and baseline visit, which can be combined. Non-invasive tests of the skin will be taken and include the skin measurements that will be performed are the same as the Moisturizer Intervention group. 2. Pediatric Study: There will be 2-3 visits for this study: a screening visit, a baseline visit, and a final visit. Infants and toddlers between 3 months and 3 years of age without a history of skin barrier diseases will be assigned to a moisturizer, which include either Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, or Aveeno Skin Relief Moisture Repair Cream. Non-invasive tests of the skin will be made at Visit 1 and after four weeks (Visit 2). - TEWL- measures how much water is lost across the skin barrier - Skin electrical capacitance - measures the moisture in the top layer of skin - Skin pH - measures the acidity of the skin

NCT ID: NCT01259323 Completed - Dermatitis Clinical Trials

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.

NCT ID: NCT01244230 Completed - Atopic Dermatitis Clinical Trials

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)

Start date: November 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: - To evaluate the long-term safety (12 weeks) - To evaluate the efficacy - To characterize the pharmacokinetic profile

NCT ID: NCT01238263 Completed - Clinical trials for Atopic Dermatitis, Serum Skin Test

Autologous Serum Skin Testing in Patients With Atopic Dermatitis Autologous Serum Skin Testing in Patients With Atopic Dermatitis

Start date: April 2009
Phase: N/A
Study type: Observational

Recently, IgE-type autoantibodies against self proteins have been detected in the serum of the atopic dermatitis patients. The role of this IgE autoantibodies involved in the pathogenesis of atopic dermatitis is not known, yet. But, there may be a correlation between the severity of the disease and the serum levels of this autoantibodies. The autologous serum skin testing is applied to both atopic dermatitis patients and healthy control and the results are estimated in this study.The investigators detected 70% positive autologous serum skin testing in atopic dermatitis patients and test positivity was higher in patients with atopy history, moderately severe disease calculated by SCORAD index and high serum IgE levels.

NCT ID: NCT01232985 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if investigational device, RD047-26, is safe and useful for the treatment of mild to moderate atopic dermatitis.

NCT ID: NCT01232543 Completed - Atopic Dermatitis Clinical Trials

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

0405-01-04
Start date: November 2010
Phase: Phase 2
Study type: Interventional

The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis

NCT ID: NCT01228513 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.

NCT ID: NCT01224132 Completed - Clinical trials for Atopic Dermatitis, Probiotics

Effect of Probiotics in the Atopic Dermatitis

Start date: October 2007
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the efficacy of probiotics in the treatment of atopic dermatitis. Probiotics in AD patients were effective in reducing SCORAD index levels, but not effective in skin prick test positivity, serum IL-2-4-5-6-10, TNF-α, IFN-γ, ECP, and serum total and specific IgE levels.

NCT ID: NCT01223222 Completed - Atopic Dermatitis Clinical Trials

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections. Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.

NCT ID: NCT01216059 Completed - Atopic Dermatitis Clinical Trials

Text Messaging and Atopic Dermatitis

Start date: October 2010
Phase: N/A
Study type: Interventional

Atopic dermatitis is a common problem faced by patients of all ages and backgrounds. Treatment regimens and specific therapies may be time consuming and multiple studies have documented a parallel decrease in compliance as time after an office visit increases. The adolescent population is an extremely challenging sub-group of patients in terms of complying with a treatment regimen. Not only are they striving for independence and thus lacking supervision of a regimen by a parent, but their complex thinking skills are immature, leading to forgetful behavior. By introducing a reminder system for these vulnerable patients that is easily incorporated into their daily lives, the investigators propose that patients will have better compliance at applying their medication and thus improving their atopic dermatitis. Text-messaging via cell phones has become very popular among teenagers and adults and provides a non-obtrusive method of sending a treatment reminder.